| Name | Title | Contact Details |
|---|
Astute Medical is committed to improving patient outcomes through the identification and validation of unique biomarkers. Our measurement methods help rapidly assess high-risk acute conditions and diseases. By incoporating useful clinical tools, we help healthcare professionals provide rapid, accurate and life-saving responses.
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.
Venus Concept is a leading developer and manufacturer of devices for the medical aesthetic market.
John R. Dwyer, Jr., JD, serves as the Chief Financial Officer and General Counsel of Telcare, Inc. Mr. Dwyer served as Principal of CodeRyte, Inc. He served as an Executive Vice President of Doctors Health, Inc. and also served as its Chief Financial Officer for 2 years. He served as a Principal of Graham, Hamilton & Dwyer, Inc. (“GHD“). He served as Chief Executive Officer of e-MEDx. He served as Chief Operating Officer of Active Health Management. He served as Chief Executive Officer of Vetcentric, a specialty on-line pharmacy. Mr. Dwyer served at Diametrics, Inc., where he served as President of California-based high technology Company. Mr. Dwyer began his professional career as an Attorney with Arent, Fox, Kintner, Plotkin & Kahn, the fifth largest law firm in Washington, D.C., where he focused on transactions in the health care and telecommunications industries. He serves as the Chairman of Redbricks.com, LLC. He serves on the Boards of a number of private and not-for-profit organizations including Earth Conservation Corp. He serves as a Director of the Trust for America's Health. He serves on the Executive Council of Leaders Engaged against Alzheimer's Disease (LEAD). He serves as a Director of USAgainstAlzheimer's. He served as the Chairman of Telcare, Inc. and serves as its Director. He served as a Director of CodeRyte, Inc. Mr. Dwyer served as a Member of the Obama Administration's HHS transition team and has played an active role in the HHS, FDA, and Commerce transition and staffing plans of the Administration. He co-founded the first political action committee focused on a particular disease, the Alzheimer's Action PAC. Mr. Dwyer is a frequent Speaker on financing and regulatory issues of critical importance to emerging health technology companies. He has spoken on health information issues, business risks associated with the FDA approval process, and patent insurance at a variety of forums including the BIO/CEO and AdvaMed annual conferences. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.